Date: 2014-11-12
Type of information: Private placement
Company: Cellectis (France)
Investors:
Amount: €13 million
Funding type: private placement
Planned used: These additional funds, along with the Company’s existing cash and cash equivalents, will be used to continue to execute Cellectis\' strategy focused on developing therapeutic programs and to advance product development activities at Cellectis plant sciences.
Others: * On November 12, 2014, Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), announced that it has received €13,237,524 ($16.5M) through the exercise of 7,354,180 warrants of the 12,195,113 warrants issued in October 2011, which expired on October 28, 2014 (60.3% of the total amount). An additional 1,470,836 new shares were issued as a result of such exercise.
Therapeutic area:
